Blog

Rahul Gosain: FDA approval of Fruquintinib from FRESCO2 and how it fits in our Rx paradigm with N. Arvind Dasari

Photos of Rahul and Rohit Gosain, and Arvind Dasari

Apr 29, 2024, 07:58

Rahul Gosain: FDA approval of Fruquintinib from FRESCO2 and how it fits in our Rx paradigm with N. Arvind Dasari

Rahul Gosain, Co-Founder of Oncology Brothers podcast and Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, recently shared on LinkedIn:

“GISeries: In this episode, we get a chance to discuss FDA approval of Fruquintinib from FRESCO2 and how it fits in our treatment paradigm with N. Arvind Dasari.

Full Interview:
– On Targeted Oncology,
– On OncBrothers,
– Also on the ‘Oncology Brothers’ podcast.”

View the attached video.
Source: Rahul Gosain/LinkedIn

cancer colorectal cancer CRC FDA FDA approval FRESCO2 trial Fruquintinib N. Arvind Dasari OncoDaily Oncology Oncology Brothers Rahul Gosain refractory CRC Targeted Oncology Wilmot Cancer Institute

Why President Biden Values Cancer Research So Much: The Story Behind Cancer Moonshot

The 2024 NIH Director’s Awards

Tedros Adhanom Ghebreyesus Received 2024 Rebranding Africa Forum Governance Leadership Award

Highlights from SIOP 2024 Congress

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 8

Special Coverage